The emergence of PD-(L1) treatments has provided patients options where previously none existed, and the leading forms of these therapies have gone on to blockbuster sales.
Adoption of biosimilars in the US has been notoriously slow, but biosimilars manufacturers and outside observers expect this to change rapidly in the coming years.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
